Is methamphetamine use associated with idiopathic pulmonary arterial hypertension?

Kelly M. Chin, Richard N. Channick, Lewis J. Rubin

Research output: Contribution to journalArticle

121 Citations (Scopus)

Abstract

Background: Amphetamine, methamphetamine, and cocaine are suspected of being pulmonary hypertension risk factors based on a small number of case reports along with pharmacologic similarities to fenfluramine, a diet drug associated with pulmonary arterial hypertension (PAH). We sought to determine whether rates of stimulant use are increased in patients believed to have idiopathic PAH compared with patients with PAH and known risk factors and patients with chronic thromboembolic pulmonary hypertension (CTEPH). Methods: In this retrospective study, rates of stimulant use were determined for 340 patients with idiopathic PAH, PAH and known risk factors, or CTEPH seen between November 2002 and April 2004. "Stimulant" use was defined as any reported use of amphetamine, methamphetamine, or cocaine. Odds of stimulant use were calculated using a polychotomous logistic regression model. Results: A history of stimulant use was found in 28.9% of patients with a diagnosis of idiopathic PAH, compared with 3.8% of patients with PAH and a known risk factor, and 4.3% of patients with CTEPH. After adjustment for differences in age, patients with idiopathic PAH were 10.14 times (95% confidence interval, 3.39 to 30.3; p < 0.0001) more likely to have used stimulants than patients with PAH and known risk factors, and 7.63 times (95% confidence interval, 2.99 to 19.5; p < 0.0001) more likely to have used stimulants than patients with CTEPH. Conclusions: Patients with idiopathic PAH are significantly more likely to have used stimulants than patients with other forms of pulmonary hypertension.

Original languageEnglish (US)
Pages (from-to)1657-1663
Number of pages7
JournalChest
Volume130
Issue number6
DOIs
StatePublished - Dec 2006

Fingerprint

Methamphetamine
Pulmonary Hypertension
Amphetamine
Cocaine
Familial Primary Pulmonary Hypertension
Logistic Models
Confidence Intervals
Fenfluramine
Retrospective Studies

Keywords

  • Illicit drugs
  • Methamphetamine
  • Pulmonary hypertension
  • Risk factors

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Is methamphetamine use associated with idiopathic pulmonary arterial hypertension? / Chin, Kelly M.; Channick, Richard N.; Rubin, Lewis J.

In: Chest, Vol. 130, No. 6, 12.2006, p. 1657-1663.

Research output: Contribution to journalArticle

Chin, Kelly M. ; Channick, Richard N. ; Rubin, Lewis J. / Is methamphetamine use associated with idiopathic pulmonary arterial hypertension?. In: Chest. 2006 ; Vol. 130, No. 6. pp. 1657-1663.
@article{36f3a2bca1f64dd89040362ff44269f6,
title = "Is methamphetamine use associated with idiopathic pulmonary arterial hypertension?",
abstract = "Background: Amphetamine, methamphetamine, and cocaine are suspected of being pulmonary hypertension risk factors based on a small number of case reports along with pharmacologic similarities to fenfluramine, a diet drug associated with pulmonary arterial hypertension (PAH). We sought to determine whether rates of stimulant use are increased in patients believed to have idiopathic PAH compared with patients with PAH and known risk factors and patients with chronic thromboembolic pulmonary hypertension (CTEPH). Methods: In this retrospective study, rates of stimulant use were determined for 340 patients with idiopathic PAH, PAH and known risk factors, or CTEPH seen between November 2002 and April 2004. {"}Stimulant{"} use was defined as any reported use of amphetamine, methamphetamine, or cocaine. Odds of stimulant use were calculated using a polychotomous logistic regression model. Results: A history of stimulant use was found in 28.9{\%} of patients with a diagnosis of idiopathic PAH, compared with 3.8{\%} of patients with PAH and a known risk factor, and 4.3{\%} of patients with CTEPH. After adjustment for differences in age, patients with idiopathic PAH were 10.14 times (95{\%} confidence interval, 3.39 to 30.3; p < 0.0001) more likely to have used stimulants than patients with PAH and known risk factors, and 7.63 times (95{\%} confidence interval, 2.99 to 19.5; p < 0.0001) more likely to have used stimulants than patients with CTEPH. Conclusions: Patients with idiopathic PAH are significantly more likely to have used stimulants than patients with other forms of pulmonary hypertension.",
keywords = "Illicit drugs, Methamphetamine, Pulmonary hypertension, Risk factors",
author = "Chin, {Kelly M.} and Channick, {Richard N.} and Rubin, {Lewis J.}",
year = "2006",
month = "12",
doi = "10.1378/chest.130.6.1657",
language = "English (US)",
volume = "130",
pages = "1657--1663",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "6",

}

TY - JOUR

T1 - Is methamphetamine use associated with idiopathic pulmonary arterial hypertension?

AU - Chin, Kelly M.

AU - Channick, Richard N.

AU - Rubin, Lewis J.

PY - 2006/12

Y1 - 2006/12

N2 - Background: Amphetamine, methamphetamine, and cocaine are suspected of being pulmonary hypertension risk factors based on a small number of case reports along with pharmacologic similarities to fenfluramine, a diet drug associated with pulmonary arterial hypertension (PAH). We sought to determine whether rates of stimulant use are increased in patients believed to have idiopathic PAH compared with patients with PAH and known risk factors and patients with chronic thromboembolic pulmonary hypertension (CTEPH). Methods: In this retrospective study, rates of stimulant use were determined for 340 patients with idiopathic PAH, PAH and known risk factors, or CTEPH seen between November 2002 and April 2004. "Stimulant" use was defined as any reported use of amphetamine, methamphetamine, or cocaine. Odds of stimulant use were calculated using a polychotomous logistic regression model. Results: A history of stimulant use was found in 28.9% of patients with a diagnosis of idiopathic PAH, compared with 3.8% of patients with PAH and a known risk factor, and 4.3% of patients with CTEPH. After adjustment for differences in age, patients with idiopathic PAH were 10.14 times (95% confidence interval, 3.39 to 30.3; p < 0.0001) more likely to have used stimulants than patients with PAH and known risk factors, and 7.63 times (95% confidence interval, 2.99 to 19.5; p < 0.0001) more likely to have used stimulants than patients with CTEPH. Conclusions: Patients with idiopathic PAH are significantly more likely to have used stimulants than patients with other forms of pulmonary hypertension.

AB - Background: Amphetamine, methamphetamine, and cocaine are suspected of being pulmonary hypertension risk factors based on a small number of case reports along with pharmacologic similarities to fenfluramine, a diet drug associated with pulmonary arterial hypertension (PAH). We sought to determine whether rates of stimulant use are increased in patients believed to have idiopathic PAH compared with patients with PAH and known risk factors and patients with chronic thromboembolic pulmonary hypertension (CTEPH). Methods: In this retrospective study, rates of stimulant use were determined for 340 patients with idiopathic PAH, PAH and known risk factors, or CTEPH seen between November 2002 and April 2004. "Stimulant" use was defined as any reported use of amphetamine, methamphetamine, or cocaine. Odds of stimulant use were calculated using a polychotomous logistic regression model. Results: A history of stimulant use was found in 28.9% of patients with a diagnosis of idiopathic PAH, compared with 3.8% of patients with PAH and a known risk factor, and 4.3% of patients with CTEPH. After adjustment for differences in age, patients with idiopathic PAH were 10.14 times (95% confidence interval, 3.39 to 30.3; p < 0.0001) more likely to have used stimulants than patients with PAH and known risk factors, and 7.63 times (95% confidence interval, 2.99 to 19.5; p < 0.0001) more likely to have used stimulants than patients with CTEPH. Conclusions: Patients with idiopathic PAH are significantly more likely to have used stimulants than patients with other forms of pulmonary hypertension.

KW - Illicit drugs

KW - Methamphetamine

KW - Pulmonary hypertension

KW - Risk factors

UR - http://www.scopus.com/inward/record.url?scp=33845942152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845942152&partnerID=8YFLogxK

U2 - 10.1378/chest.130.6.1657

DO - 10.1378/chest.130.6.1657

M3 - Article

C2 - 17166979

AN - SCOPUS:33845942152

VL - 130

SP - 1657

EP - 1663

JO - Chest

JF - Chest

SN - 0012-3692

IS - 6

ER -